Short interfering RNAs, or siRNAs, belong to a class of RNA species which play a role in both cellular defence and gene regulation. siRNAs comprise a larger portion of the RNA interference pathway that includes the degradation of RNAs which possess complementarily to specific target sequences. This property has given siRNA technology the potential to become a powerful new tool for a wide variety of disciplines, ranging from the design of novel anti-cancer agents to applications in agriculture. The following review outlines patents that have been issued over the past 6 months concerning siRNA technology. Patents are discussed which encompass improved delivery systems for cellular uptake of siRNAs, new therapeutics to combat human diseases, and unique uses of siRNAs to advance plant science. The review also provides detailed lists of the most recent patents that have been issued which cover these areas of siRNA technology, and paves the way for future innovations based on RNA interference in the life sciences.
Keywords: siRNA, short interfering RNA, RNA interference, human disease, plant sciences, viral and nonviral delivery vehicles, nanocarriers, liposomes, PTGS, Caenorhabditis elegans, double-stranded RNA, RISC, miRNAs, oncogenes, tumor suppressors, gene therapy, nanoliposome, Cholesterol, SNALP, Fab, Aptamer, Nanoparticle, Lentivirus, Adenovirus, AAV, TATA box, gene silencing, YCWP, synthetic polymers, hematopoiesis, RCRs, LTR, Hepatitis B virus, CHB, cirrhosis, Arginine-conjugated bioreducible poly (disulfide amine) polymers, US20100005317, W02009058913A3, FLiPs, lipophile, LNA, rheumatoid arthritis, cancer, US7632937, WO2009154999A2, Plk, Wnts, Drosophila, WIF-1, proto-oncogene, leukemia, US7622455, SOD1, tyrosine kinase, interleukin, ICAM1, IGF-1R, CYP3A4, TNFalpha, RTP801L, alopecia, Alzheimer's disease, Parkinson's disease, Huntington's disease, Spinocerebellar Ataxia, Nicotiana tabacum, Brassica, Zea mays, QPRTase, 20090285784